PTAFR and neoplasm: Importantly, pharmacological inhibitors of cyclooxygenase type 2 (COX-2) or depleting antibodies against Tregs attenuate PAFR-mediated systemic immunosuppression, and tumor growth, as well as enhance the efficacy of chemotherapeutic agents and radiation therapy in experimental cancer models [9, 14].